4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-YL]benzenesulfonamide for the treatment of inflammation or an inflammation-associated disorder
US RE44,048 In forceTerm ends Mar 5, 2030 · From the USPTO record
20-year base term ends Mar 5, 2030
Nov 30, 1993
Mar 5, 2030
Mar 5, 2013
How we calculated this date
| Step | Input | Date after this step | Confidence |
|---|---|---|---|
| Base term, the 1995 transition rule | Granted Mar 5, 2013 + 17 years, or clock starts Nov 30, 1993 + 20 years, whichever is later | Mar 5, 2030 | High confidence |
| Continuity chain | A reissue: its term follows the original patent's, with the original's term adjustment | follows the original patent | Medium confidence |
| Patent term adjustment | No term adjustment record on a grant after 2005, so none is added | no change | Medium confidence |
| Terminal disclaimer cap | None on record | no cap applied | High confidence |
| Patent term extension | None on file | no change | High confidence |
| Fee events | No fee event states this; the fee state is read from the payments the fee record holds | In force | Medium confidence |
| Computed term end | The steps above, in order | Mar 5, 2030 | From the USPTO record |
Sources
Google Patents · The patent document at USPTO · Assignment records at USPTO
USPTO account required: This application in Patent Center · USPTO's maintenance fee lookup
Maintenance fee events come from USPTO's own fee records. Its fee lookup asks for the patent number and the application number.
Not on this page: the patent's family, its recorded assignments and its citation count. USPTO's assignment records, linked above, list every recorded assignment.
Every date shows its work: the base term, any term adjustment or extension, any disclaimer cap, and the maintenance fee record, each with a confidence tier. How this record was built
Computed patent terms end on the dates shown. Related patents and pending applications may cover overlapping subject matter.
In force means the term is running and no lapse is on record. It is not a finding that the patent is valid.